AU2011271046B2 - Hybrid light chain mice - Google Patents
Hybrid light chain mice Download PDFInfo
- Publication number
- AU2011271046B2 AU2011271046B2 AU2011271046A AU2011271046A AU2011271046B2 AU 2011271046 B2 AU2011271046 B2 AU 2011271046B2 AU 2011271046 A AU2011271046 A AU 2011271046A AU 2011271046 A AU2011271046 A AU 2011271046A AU 2011271046 B2 AU2011271046 B2 AU 2011271046B2
- Authority
- AU
- Australia
- Prior art keywords
- mouse
- human
- light chain
- gene
- locus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000699670 Mus sp. Species 0.000 title abstract description 121
- 238000000034 method Methods 0.000 claims abstract description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 561
- 210000004027 cell Anatomy 0.000 claims description 75
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 59
- 101000777315 Mus musculus Choline kinase alpha Proteins 0.000 claims description 57
- 101000777310 Mus musculus Choline/ethanolamine kinase Proteins 0.000 claims description 57
- 101000974705 Mus musculus UMP-CMP kinase Proteins 0.000 claims description 57
- 239000000427 antigen Substances 0.000 claims description 49
- 108091007433 antigens Proteins 0.000 claims description 49
- 102000036639 antigens Human genes 0.000 claims description 49
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 41
- 108060003951 Immunoglobulin Proteins 0.000 claims description 40
- 102000018358 immunoglobulin Human genes 0.000 claims description 40
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 39
- 210000001161 mammalian embryo Anatomy 0.000 claims description 14
- 230000028993 immune response Effects 0.000 claims description 13
- 210000004408 hybridoma Anatomy 0.000 claims description 8
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 4
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 650
- 102000025171 antigen binding proteins Human genes 0.000 abstract description 14
- 108091000831 antigen binding proteins Proteins 0.000 abstract description 14
- 108700019146 Transgenes Proteins 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 6
- 230000008685 targeting Effects 0.000 description 169
- 239000013598 vector Substances 0.000 description 97
- 239000012634 fragment Substances 0.000 description 65
- 108700028369 Alleles Proteins 0.000 description 45
- 150000007523 nucleic acids Chemical group 0.000 description 42
- 108020004414 DNA Proteins 0.000 description 37
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 35
- 238000003780 insertion Methods 0.000 description 32
- 230000037431 insertion Effects 0.000 description 32
- 108091029795 Intergenic region Proteins 0.000 description 31
- 108091028043 Nucleic acid sequence Proteins 0.000 description 30
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 28
- 101150076615 ck gene Proteins 0.000 description 28
- 238000012217 deletion Methods 0.000 description 27
- 230000037430 deletion Effects 0.000 description 27
- 229930193140 Neomycin Natural products 0.000 description 26
- 229960004927 neomycin Drugs 0.000 description 26
- 210000004988 splenocyte Anatomy 0.000 description 24
- 230000006798 recombination Effects 0.000 description 22
- 238000005215 recombination Methods 0.000 description 22
- 230000004048 modification Effects 0.000 description 21
- 238000012986 modification Methods 0.000 description 21
- 238000011144 upstream manufacturing Methods 0.000 description 20
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 19
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 19
- 210000001185 bone marrow Anatomy 0.000 description 19
- 108010091086 Recombinases Proteins 0.000 description 17
- 102000018120 Recombinases Human genes 0.000 description 17
- 238000010240 RT-PCR analysis Methods 0.000 description 16
- 239000003623 enhancer Substances 0.000 description 16
- 230000006801 homologous recombination Effects 0.000 description 15
- 238000002744 homologous recombination Methods 0.000 description 15
- 238000013459 approach Methods 0.000 description 14
- 238000013518 transcription Methods 0.000 description 14
- 230000035897 transcription Effects 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 13
- 101150008942 J gene Proteins 0.000 description 12
- 108091008053 gene clusters Proteins 0.000 description 11
- 238000012239 gene modification Methods 0.000 description 11
- 230000005017 genetic modification Effects 0.000 description 11
- 235000013617 genetically modified food Nutrition 0.000 description 11
- 230000008707 rearrangement Effects 0.000 description 11
- 101150117115 V gene Proteins 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 101150003160 X gene Proteins 0.000 description 8
- 101150028074 2 gene Proteins 0.000 description 7
- 101150090724 3 gene Proteins 0.000 description 7
- 101150101112 7 gene Proteins 0.000 description 7
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 101000994437 Homo sapiens Protein jagged-1 Proteins 0.000 description 7
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 7
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 7
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 101100384399 Mus musculus C2 gene Proteins 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 210000003297 immature b lymphocyte Anatomy 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 101150111062 C gene Proteins 0.000 description 6
- 230000011712 cell development Effects 0.000 description 6
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 238000002864 sequence alignment Methods 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 101150097493 D gene Proteins 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 101150043003 Htt gene Proteins 0.000 description 4
- 108090000144 Human Proteins Proteins 0.000 description 4
- 102000003839 Human Proteins Human genes 0.000 description 4
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 101150037671 hicd gene Proteins 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 101150084750 1 gene Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101000777314 Homo sapiens Choline kinase alpha Proteins 0.000 description 3
- 101000777313 Homo sapiens Choline/ethanolamine kinase Proteins 0.000 description 3
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 3
- 101001138544 Homo sapiens UMP-CMP kinase Proteins 0.000 description 3
- 102100039564 Leukosialin Human genes 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 102000023732 binding proteins Human genes 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 3
- 229960000268 spectinomycin Drugs 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108091008109 Pseudogenes Proteins 0.000 description 2
- 102000057361 Pseudogenes Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 238000011577 humanized mouse model Methods 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 210000000472 morula Anatomy 0.000 description 2
- 108700039855 mouse a Proteins 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 101150066838 12 gene Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101150106899 28 gene Proteins 0.000 description 1
- 101150017816 40 gene Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 101150042441 K gene Proteins 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100003131 Mus musculus Atp8b1 gene Proteins 0.000 description 1
- 101100060131 Mus musculus Cdk5rap2 gene Proteins 0.000 description 1
- 101100060035 Mus musculus Cic gene Proteins 0.000 description 1
- 101100448575 Mus musculus Gli1 gene Proteins 0.000 description 1
- 101100188802 Mus musculus Hcrt gene Proteins 0.000 description 1
- 101100365003 Mus musculus Scel gene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241001105470 Valenzuela Species 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- -1 antibodies) Proteins 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000146 jump and return pulse sequence Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 101150006608 ox gene Proteins 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Environmental Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Position Input By Displaying (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015275242A AU2015275242B2 (en) | 2010-06-22 | 2015-12-22 | Hybrid light chain mice |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35731410P | 2010-06-22 | 2010-06-22 | |
| US35731710P | 2010-06-22 | 2010-06-22 | |
| US61/357,317 | 2010-06-22 | ||
| US61/357,314 | 2010-06-22 | ||
| PCT/US2011/041370 WO2011163314A1 (en) | 2010-06-22 | 2011-06-22 | Hybrid light chain mice |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015275242A Division AU2015275242B2 (en) | 2010-06-22 | 2015-12-22 | Hybrid light chain mice |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2011271046A1 AU2011271046A1 (en) | 2013-01-31 |
| AU2011271046B2 true AU2011271046B2 (en) | 2015-10-01 |
Family
ID=44509861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011271046A Active AU2011271046B2 (en) | 2010-06-22 | 2011-06-22 | Hybrid light chain mice |
Country Status (30)
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DK2346994T3 (da) | 2008-09-30 | 2022-02-28 | Ablexis Llc | Knock-in-mus til fremstilling af kimære antistoffer |
| RU2011129459A (ru) | 2008-12-18 | 2013-01-27 | Эрасмус Юниверсити Медикал Сентр Роттердам | Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| EP2517556B2 (en) | 2009-07-08 | 2023-03-22 | Kymab Limited | Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| WO2011097603A1 (en) | 2010-02-08 | 2011-08-11 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| KR102004106B1 (ko) | 2010-03-31 | 2019-07-25 | 아블렉시스, 엘엘씨 | 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작 |
| SMT201900241T1 (it) | 2010-06-22 | 2019-05-10 | Regeneron Pharma | Topi esprimenti una catena leggera ibrida di immunoglobulina con una regione variabile umana |
| DK2597945T3 (da) | 2010-07-26 | 2020-09-21 | Trianni Inc | Transgene dyr og fremgangsmåder til anvendelse deraf |
| US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| RS55495B1 (sr) | 2010-08-02 | 2017-04-28 | Regeneron Pharma | Miševi koji stvaraju vezujuće proteine koji sadrže vl domene |
| SI3865581T1 (sl) | 2011-08-05 | 2024-12-31 | Regeneron Pharmaceuticals, Inc. | Miši s humanizirano univerzalno lahko verigo |
| CA2846319A1 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
| JP2014531452A (ja) * | 2011-09-19 | 2014-11-27 | カイマブ・リミテッド | 動物、レパートリーおよび方法 |
| EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| US9253965B2 (en) * | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| PL2793567T3 (pl) * | 2011-12-20 | 2019-09-30 | Regeneron Pharmaceuticals, Inc. | Myszy z humanizowanym łańcuchem lekkim |
| HUE045537T2 (hu) | 2012-03-16 | 2019-12-30 | Regeneron Pharma | PH-érzékeny immunglobulin-szekvenciákat expresszáló rágcsálók |
| AU2013204581B2 (en) | 2012-03-16 | 2015-06-25 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| RU2644684C2 (ru) | 2012-03-16 | 2018-02-13 | Регенерон Фармасьютикалз, Инк. | Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| JP2015512635A (ja) | 2012-03-28 | 2015-04-30 | カイマブ・リミテッド | クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物 |
| WO2014130690A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
| EP4545567A3 (en) * | 2013-03-13 | 2025-08-13 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US9980470B2 (en) | 2013-03-14 | 2018-05-29 | Erasmus University Medical Center | Antibody production |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| LT3046412T (lt) * | 2013-09-18 | 2019-07-25 | Regeneron Pharmaceuticals, Inc. | Histidino pakeitimus lengvoje grandinėje turintys antikūnai ir genetiškai modifikuoti gyvūnai, išskyrus žmogų, išvesti jų gamybai |
| ES2993142T3 (en) | 2013-10-01 | 2024-12-23 | Kymab Ltd | Animal models and therapeutic molecules |
| WO2015103999A1 (en) * | 2014-01-10 | 2015-07-16 | Hung Alfur Fu-Hsin | Transgenic animals capable of producing humanized ige at much higher levels than mouse ige |
| ES2872475T3 (es) | 2014-03-21 | 2021-11-02 | Regeneron Pharma | Animales no humanos que producen proteínas de unión de dominio único |
| WO2015143406A2 (en) * | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
| MY181896A (en) | 2014-06-06 | 2021-01-12 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| JP2017529841A (ja) | 2014-09-19 | 2017-10-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | キメラ抗原受容体 |
| JP2017531642A (ja) | 2014-10-03 | 2017-10-26 | マサチューセッツ インスティテュート オブ テクノロジー | エボラ糖タンパク質に結合する抗体およびその使用 |
| US10100129B2 (en) | 2014-11-21 | 2018-10-16 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| PL3233912T3 (pl) | 2014-12-19 | 2021-12-27 | Regenesance B.V. | Przeciwciała, które wiążą ludzkie c6 oraz ich zastosowania |
| EP3237448A1 (en) | 2014-12-23 | 2017-11-01 | Bristol-Myers Squibb Company | Antibodies to tigit |
| ES2721775T3 (es) | 2015-02-05 | 2019-08-05 | Basf Se | Central solar con un primer circuito de portador de calor y un segundo circuito de portador de calor |
| JP2018508224A (ja) | 2015-03-19 | 2018-03-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗原を結合する軽鎖可変領域を選択する非ヒト動物 |
| HUE061253T2 (hu) | 2015-05-29 | 2023-06-28 | Bristol Myers Squibb Co | Antitestek OX40 ellen és azok felhasználásai |
| MX2017016502A (es) | 2015-06-29 | 2018-03-12 | Univ Rockefeller | Anticuerpos contra cd40 con actividad agonista mejorada. |
| CN105274116B (zh) * | 2015-10-21 | 2020-09-29 | 重庆金迈博生物科技有限公司 | 一种制备人源化抗体的核酸分子及其应用 |
| JP6983776B2 (ja) | 2015-11-19 | 2021-12-17 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用 |
| US10813346B2 (en) | 2015-12-03 | 2020-10-27 | Trianni, Inc. | Enhanced immunoglobulin diversity |
| US11053288B2 (en) | 2016-02-04 | 2021-07-06 | Trianni, Inc. | Enhanced production of immunoglobulins |
| KR20220033522A (ko) | 2016-03-04 | 2022-03-16 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| EP4406550A3 (en) | 2016-03-04 | 2024-10-16 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
| EP3455256A1 (en) | 2016-05-09 | 2019-03-20 | Bristol-Myers Squibb Company | Tl1a antibodies and uses thereof |
| AU2017268458B2 (en) | 2016-05-20 | 2022-07-21 | Regeneron Pharmaceuticals, Inc. | Methods for breaking immunological tolerance using multiple guide RNAS |
| EP3462853B1 (en) | 2016-06-03 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Rodents expressing exogenous terminal deoxynucleotidyltransferase |
| WO2017214089A1 (en) | 2016-06-06 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies with human lambda light chains |
| US20170371963A1 (en) * | 2016-06-27 | 2017-12-28 | Facebook, Inc. | Systems and methods for identifying matching content |
| EP4512829A3 (en) | 2016-07-14 | 2025-06-11 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| WO2018044970A1 (en) | 2016-08-31 | 2018-03-08 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof |
| CR20210094A (es) | 2016-10-13 | 2021-03-31 | Massachusetts Inst Technology | ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193) |
| US12063913B2 (en) | 2016-10-31 | 2024-08-20 | National University Corporation Tottori University | Human antibody-producing non-human animal and method for preparing human antibodies using same |
| PL3766343T3 (pl) | 2016-11-04 | 2022-09-26 | Regeneron Pharmaceuticals, Inc. | Zwierzęta inne niż człowiek posiadające zmodyfikowany sposobami inżynierii locus łańcucha lekkiego lambda immunoglobuliny |
| KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| PT3720279T (pt) * | 2017-12-05 | 2022-10-06 | Regeneron Pharma | Ratinhos tendo uma cadeia leve lambda de imunoglobulina manipulada e seus usos |
| CN120192415A (zh) | 2018-01-12 | 2025-06-24 | 百时美施贵宝公司 | 抗tim3抗体及其用途 |
| EP3768715A1 (en) | 2018-03-23 | 2021-01-27 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| HUE070158T2 (hu) | 2018-03-24 | 2025-05-28 | Regeneron Pharma | Genetikailag módosított egerek vagy patkányok peptid-mhc komplexek elleni terápiás antitestek létrehozásra, ezek elõállítására szolgáló módszerek, valamint alkalmazásuk |
| AU2019242586B2 (en) | 2018-03-26 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
| US11337409B2 (en) | 2018-06-08 | 2022-05-24 | Crystal Bioscience Inc. | Transgenic animal for producing diversified antibodies that have the same light chain I |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| CN112969929B (zh) | 2018-10-26 | 2024-06-21 | 日本汽车能源株式会社 | 电池控制装置 |
| SG11202104969RA (en) | 2018-11-16 | 2021-06-29 | Bristol Myers Squibb Co | Anti-nkg2a antibodies and uses thereof |
| KR20230128134A (ko) | 2019-01-22 | 2023-09-01 | 브리스톨-마이어스 스큅 컴퍼니 | Il-7r 알파 서브유닛에 대한 항체 및 이의 용도 |
| AU2020226865A1 (en) | 2019-02-22 | 2021-07-29 | Regeneron Pharmaceuticals, Inc. | Rodents having genetically modified sodium channels and methods of use thereof |
| CA3136478A1 (en) * | 2019-06-05 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof |
| CN114554841B (zh) * | 2019-07-01 | 2024-06-11 | 特里安尼公司 | 转基因哺乳动物及其使用方法 |
| EP4069722A1 (en) | 2019-12-02 | 2022-10-12 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
| US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
| JP2023541216A (ja) * | 2020-06-25 | 2023-09-29 | ヒューマブ カンパニー リミテッド | ヘテロ接合型トランスジェニック動物 |
| IL301137A (en) | 2020-09-11 | 2023-05-01 | Regeneron Pharma | Identification and production of antigen-specific antibodies |
| CN116848254A (zh) | 2020-12-16 | 2023-10-03 | 瑞泽恩制药公司 | 表达人源化Fcα受体的小鼠 |
| EP4559939A3 (en) | 2020-12-23 | 2025-09-24 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses therof |
| US12371487B2 (en) | 2020-12-23 | 2025-07-29 | Regeneron Pharmaceuticals, Inc. | Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same |
| WO2023199655A1 (ja) | 2022-04-13 | 2023-10-19 | 日本精工株式会社 | 軸受装置の状態の検出方法、検出装置、およびプログラム |
| USD999969S1 (en) * | 2022-04-29 | 2023-09-26 | Shenzhen Intellirocks Tech. Co., Ltd. | Lamp |
| EP4658687A1 (en) | 2023-01-31 | 2025-12-10 | University of Rochester | Immune checkpoint blockade therapy for treating staphylococcus aureus infections |
| TW202509069A (zh) | 2023-05-04 | 2025-03-01 | 美商諾瓦森塔股份有限公司 | 抗cd161抗體及其使用方法 |
| WO2025184208A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000026373A1 (en) * | 1998-11-03 | 2000-05-11 | Babraham Institute | MURINE EXPRESSION OF HUMAN Igμ LOCUS |
| US20030217373A1 (en) * | 2001-11-30 | 2003-11-20 | Green Larry L. | Transgenic animals bearing human Ig-lambda light chain genes |
| US20050060763A1 (en) * | 2001-06-21 | 2005-03-17 | Marianne Bruggeman | Mouse lambda light chain locus |
| US20060015957A1 (en) * | 1991-08-28 | 2006-01-19 | Genpharm International, Inc. | Transgenic non-human animals for producing chimeric antibodies |
| WO2009143472A2 (en) * | 2008-05-23 | 2009-11-26 | Aliva Biopharmaceuticals, Inc. | Method of generating single vl domain antibodies in transgenic animals |
| WO2010039900A2 (en) * | 2008-09-30 | 2010-04-08 | Aliva Biopharmaceuticals, Inc. | Non-human mammals for the production of chimeric antibodies |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5658727A (en) | 1991-04-10 | 1997-08-19 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US6632976B1 (en) | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
| EP2305027B1 (en) * | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
| CN101498731A (zh) * | 2000-05-18 | 2009-08-05 | 日本烟草产业株式会社 | 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途 |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| MXPA03004793A (es) * | 2000-11-30 | 2004-12-03 | Medarex Inc | Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos. |
| GB0031284D0 (en) * | 2000-12-21 | 2001-01-31 | Ks Biomedix Ltd | High affinity antibodies |
| CA2446968C (en) * | 2001-05-11 | 2012-07-03 | Kirin Beer Kabushiki Kaisha | Human artificial chromosome containing human antibody .lambda. light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission |
| US20030217171A1 (en) | 2002-05-17 | 2003-11-20 | Von Stuermer Wolfgang R. | Self-replicating and self-installing software apparatus |
| CN103205436B (zh) * | 2003-07-15 | 2016-05-25 | 人类多克隆治疗公司 | 人源化免疫球蛋白基因座 |
| CN1605628A (zh) * | 2003-09-03 | 2005-04-13 | 中国疾病预防控制中心病毒病预防控制所 | Cho细胞生产的人源抗甲肝病毒基因工程抗体 |
| CN102942631B (zh) * | 2004-08-05 | 2015-03-25 | 健泰科生物技术公司 | 人源化抗c-met拮抗剂 |
| PL1802193T3 (pl) | 2004-10-19 | 2014-09-30 | Regeneron Pharma | Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej |
| KR100971497B1 (ko) * | 2004-12-29 | 2010-07-21 | 주식회사유한양행 | 인간 종양괴사인자-알파에 특이적으로 결합하는 인간화항체 |
| EP2003960B1 (en) | 2006-03-31 | 2015-06-10 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| JP2010501165A (ja) * | 2006-08-22 | 2010-01-21 | ジーツー インフラメイション プロプライエタリー リミテッド | 抗体の作製方法 |
| DK2769992T3 (da) | 2006-10-02 | 2021-03-22 | Regeneron Pharma | Humane antistoffer med høj affinitet for human IL-4-receptor |
| US7864492B2 (en) | 2006-10-31 | 2011-01-04 | Siemens Industry, Inc. | Systems and methods for arc fault detection |
| DE102007045897A1 (de) | 2007-09-26 | 2009-04-09 | Carl Zeiss Microimaging Gmbh | Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe |
| CA2721231C (en) * | 2008-04-14 | 2015-10-06 | Innovative Targeting Solutions Inc. | Sequence diversity generation in immunoglobulins |
| RU2011129459A (ru) * | 2008-12-18 | 2013-01-27 | Эрасмус Юниверсити Медикал Сентр Роттердам | Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение |
| EP2517556B2 (en) * | 2009-07-08 | 2023-03-22 | Kymab Limited | Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains |
| WO2011097603A1 (en) * | 2010-02-08 | 2011-08-11 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| SG186238A1 (en) | 2010-06-17 | 2013-01-30 | Kymab Ltd | Animal models and therapeutic molecules |
| SMT201900241T1 (it) | 2010-06-22 | 2019-05-10 | Regeneron Pharma | Topi esprimenti una catena leggera ibrida di immunoglobulina con una regione variabile umana |
-
2011
- 2011-06-22 SM SM20190241T patent/SMT201900241T1/it unknown
- 2011-06-22 CN CN201410535091.9A patent/CN104404050B/zh active Active
- 2011-06-22 HU HUE14198318A patent/HUE036597T2/hu unknown
- 2011-06-22 DK DK16154526.4T patent/DK3034608T3/da active
- 2011-06-22 US US13/166,171 patent/US9012717B2/en active Active
- 2011-06-22 SG SG10201504568YA patent/SG10201504568YA/en unknown
- 2011-06-22 MX MX2012015300A patent/MX336344B/es unknown
- 2011-06-22 RS RS20160496A patent/RS55037B1/sr unknown
- 2011-06-22 CN CN201180038415.2A patent/CN103068994B/zh active Active
- 2011-06-22 ES ES12195716.1T patent/ES2576928T3/es active Active
- 2011-06-22 ES ES14198318.9T patent/ES2646052T3/es active Active
- 2011-06-22 PT PT117285098T patent/PT2480676E/pt unknown
- 2011-06-22 NZ NZ626979A patent/NZ626979A/en unknown
- 2011-06-22 ES ES11728508.0T patent/ES2575223T3/es active Active
- 2011-06-22 KR KR1020197002903A patent/KR102001430B1/ko active Active
- 2011-06-22 SI SI201130889A patent/SI2568049T1/sl unknown
- 2011-06-22 SI SI201130810A patent/SI2480676T1/sl unknown
- 2011-06-22 RU RU2013102596/10A patent/RU2590594C2/ru active
- 2011-06-22 ME MEP-2019-128A patent/ME03386B/me unknown
- 2011-06-22 ME MEP-2016-87A patent/ME02444B/me unknown
- 2011-06-22 LT LTEP12195716.1T patent/LT2568049T/lt unknown
- 2011-06-22 NZ NZ707198A patent/NZ707198A/en unknown
- 2011-06-22 PL PL14198318T patent/PL2905338T3/pl unknown
- 2011-06-22 US US13/166,200 patent/US9035128B2/en active Active
- 2011-06-22 PT PT16154526T patent/PT3034608T/pt unknown
- 2011-06-22 EP EP12195716.1A patent/EP2568049B1/en active Active
- 2011-06-22 KR KR1020197037332A patent/KR102211911B1/ko active Active
- 2011-06-22 KR KR1020227037565A patent/KR20220150430A/ko active Pending
- 2011-06-22 SI SI201130867A patent/SI2480675T1/sl unknown
- 2011-06-22 NZ NZ627119A patent/NZ627119A/en unknown
- 2011-06-22 ME MEP-2016-132A patent/ME02440B/me unknown
- 2011-06-22 RS RS20160483A patent/RS54891B1/sr unknown
- 2011-06-22 AU AU2011271046A patent/AU2011271046B2/en active Active
- 2011-06-22 PL PL11728508T patent/PL2480675T3/pl unknown
- 2011-06-22 LT LTEP11728508.0T patent/LT2480675T/lt unknown
- 2011-06-22 NZ NZ605758A patent/NZ605758A/en unknown
- 2011-06-22 HR HRP20160794TT patent/HRP20160794T1/hr unknown
- 2011-06-22 KR KR1020187036167A patent/KR101970944B1/ko active Active
- 2011-06-22 CA CA2804311A patent/CA2804311C/en active Active
- 2011-06-22 MY MYPI2016000459A patent/MY194456A/en unknown
- 2011-06-22 MX MX2015008807A patent/MX348942B/es unknown
- 2011-06-22 JP JP2013516714A patent/JP5988969B2/ja active Active
- 2011-06-22 JP JP2013516716A patent/JP6009441B2/ja active Active
- 2011-06-22 PT PT141983189T patent/PT2905338T/pt unknown
- 2011-06-22 KR KR1020137001582A patent/KR101934852B1/ko active Active
- 2011-06-22 EP EP16154526.4A patent/EP3034608B1/en active Active
- 2011-06-22 KR KR1020207015360A patent/KR102193823B1/ko active Active
- 2011-06-22 CN CN201180038411.4A patent/CN103068993B/zh active Active
- 2011-06-22 HU HUE12195716A patent/HUE030285T2/en unknown
- 2011-06-22 SG SG10201504324UA patent/SG10201504324UA/en unknown
- 2011-06-22 EP EP11728509.8A patent/EP2480676B1/en active Active
- 2011-06-22 RU RU2013102595/10A patent/RU2601297C2/ru active
- 2011-06-22 SG SG2012093266A patent/SG186391A1/en unknown
- 2011-06-22 MY MYPI2016000693A patent/MY195217A/en unknown
- 2011-06-22 MY MYPI2012005500A patent/MY165287A/en unknown
- 2011-06-22 NZ NZ707200A patent/NZ707200A/en unknown
- 2011-06-22 HU HUE16154526A patent/HUE044001T2/hu unknown
- 2011-06-22 DK DK11728508.0T patent/DK2480675T3/en active
- 2011-06-22 DK DK12195716.1T patent/DK2568049T3/en active
- 2011-06-22 HU HUE11728509A patent/HUE029691T2/en unknown
- 2011-06-22 PL PL12195716T patent/PL2568049T3/pl unknown
- 2011-06-22 HU HUE11728508A patent/HUE029692T2/en unknown
- 2011-06-22 MX MX2015008806A patent/MX347318B/es unknown
- 2011-06-22 KR KR1020217017823A patent/KR102462042B1/ko active Active
- 2011-06-22 IL IL313063A patent/IL313063A/en unknown
- 2011-06-22 EP EP17162880.3A patent/EP3205726A1/en active Pending
- 2011-06-22 BR BR112012033248A patent/BR112012033248A2/pt not_active Application Discontinuation
- 2011-06-22 KR KR1020137001586A patent/KR101945352B1/ko active Active
- 2011-06-22 CA CA2803864A patent/CA2803864C/en active Active
- 2011-06-22 KR KR1020197002870A patent/KR101991234B1/ko active Active
- 2011-06-22 EP EP14198318.9A patent/EP2905338B8/en active Active
- 2011-06-22 KR KR1020197017074A patent/KR102059909B1/ko active Active
- 2011-06-22 RS RS20190533A patent/RS58736B1/sr unknown
- 2011-06-22 WO PCT/US2011/041366 patent/WO2011163311A1/en not_active Ceased
- 2011-06-22 SI SI201131325T patent/SI2905338T1/sl unknown
- 2011-06-22 ME MEP-2016-119A patent/ME02442B/me unknown
- 2011-06-22 MY MYPI2012005501A patent/MY157477A/en unknown
- 2011-06-22 KR KR1020207036106A patent/KR102320944B1/ko active Active
- 2011-06-22 MX MX2015009162A patent/MX347322B/es unknown
- 2011-06-22 RS RS20171091A patent/RS56589B1/sr unknown
- 2011-06-22 RU RU2016119423A patent/RU2724736C2/ru active
- 2011-06-22 RS RS20160548A patent/RS55042B1/sr unknown
- 2011-06-22 CN CN201410538631.9A patent/CN104342455B/zh active Active
- 2011-06-22 IL IL300712A patent/IL300712B2/en unknown
- 2011-06-22 SG SG2012093258A patent/SG186390A1/en unknown
- 2011-06-22 LT LTEP14198318.9T patent/LT2905338T/lt unknown
- 2011-06-22 KR KR1020217002982A patent/KR102266097B1/ko active Active
- 2011-06-22 SM SM20170506T patent/SMT201700506T1/it unknown
- 2011-06-22 EP EP11728508.0A patent/EP2480675B1/en active Active
- 2011-06-22 ES ES16154526T patent/ES2721749T3/es active Active
- 2011-06-22 KR KR1020187036183A patent/KR101975884B1/ko active Active
- 2011-06-22 EP EP18202954.6A patent/EP3456832A1/en active Pending
- 2011-06-22 KR KR1020197012527A patent/KR102118565B1/ko active Active
- 2011-06-22 NZ NZ605751A patent/NZ605751A/en unknown
- 2011-06-22 BR BR112012032991-0A patent/BR112012032991B1/pt active IP Right Grant
- 2011-06-22 PT PT117285080T patent/PT2480675T/pt unknown
- 2011-06-22 ME MEP-2017-244A patent/ME02902B/me unknown
- 2011-06-22 DK DK11728509.8T patent/DK2480676T3/en active
- 2011-06-22 KR KR1020237006658A patent/KR20230036157A/ko active Pending
- 2011-06-22 ES ES11728509T patent/ES2570131T3/es active Active
- 2011-06-22 WO PCT/US2011/041370 patent/WO2011163314A1/en not_active Ceased
- 2011-06-22 PL PL16154526T patent/PL3034608T3/pl unknown
- 2011-06-22 DK DK14198318.9T patent/DK2905338T3/da active
- 2011-06-22 MY MYPI2016000694A patent/MY195214A/en unknown
- 2011-06-22 PT PT121957161T patent/PT2568049T/pt unknown
- 2011-06-22 PL PL11728509.8T patent/PL2480676T3/pl unknown
- 2011-06-22 SI SI201131716T patent/SI3034608T1/sl unknown
- 2011-06-22 KR KR1020217034867A patent/KR102506001B1/ko active Active
- 2011-06-22 BR BR122020013427-5A patent/BR122020013427B1/pt active IP Right Grant
- 2011-06-22 NO NO14198318A patent/NO2905338T3/no unknown
- 2011-06-22 MY MYPI2016000695A patent/MY195212A/en unknown
- 2011-06-22 MX MX2012015298A patent/MX2012015298A/es active IP Right Grant
- 2011-06-22 HR HRP20160497TT patent/HRP20160497T1/hr unknown
- 2011-06-22 TR TR2019/05992T patent/TR201905992T4/tr unknown
- 2011-06-22 LT LTEP16154526.4T patent/LT3034608T/lt unknown
-
2012
- 2012-12-18 IL IL223719A patent/IL223719A/en active IP Right Grant
- 2012-12-18 IL IL223720A patent/IL223720A/en active IP Right Grant
- 2012-12-19 MX MX2022002117A patent/MX2022002117A/es unknown
-
2013
- 2013-01-03 ZA ZA2013/00063A patent/ZA201300063B/en unknown
- 2013-01-03 ZA ZA2013/00062A patent/ZA201300062B/en unknown
- 2013-07-18 US US13/945,573 patent/US9029628B2/en active Active
- 2013-07-18 US US13/945,582 patent/US9006511B2/en active Active
- 2013-12-18 US US14/132,412 patent/US9066502B2/en active Active
-
2014
- 2014-06-23 ZA ZA2014/04600A patent/ZA201404600B/en unknown
- 2014-06-23 ZA ZA2014/04601A patent/ZA201404601B/en unknown
- 2014-12-05 US US14/561,867 patent/US9394373B2/en active Active
-
2015
- 2015-03-03 US US14/636,784 patent/US9206261B2/en active Active
- 2015-03-04 US US14/638,424 patent/US9206262B2/en active Active
- 2015-03-04 US US14/638,429 patent/US9206263B2/en active Active
- 2015-05-18 US US14/715,145 patent/US9163092B2/en active Active
- 2015-05-18 US US14/715,147 patent/US9150662B2/en active Active
- 2015-07-15 US US14/800,257 patent/US9334333B2/en active Active
- 2015-07-15 US US14/800,263 patent/US9226484B2/en active Active
- 2015-09-07 ZA ZA2015/06598A patent/ZA201506598B/en unknown
- 2015-10-19 JP JP2015205439A patent/JP6073441B2/ja active Active
- 2015-10-19 JP JP2015205321A patent/JP6243384B2/ja active Active
- 2015-11-17 US US14/943,672 patent/US9399683B2/en active Active
- 2015-11-17 US US14/943,890 patent/US9540452B2/en active Active
-
2016
- 2016-03-06 IL IL244450A patent/IL244450A/en active IP Right Grant
- 2016-05-20 CY CY20161100440T patent/CY1117537T1/el unknown
- 2016-06-28 CY CY20161100585T patent/CY1117692T1/el unknown
- 2016-07-05 SM SM201600212T patent/SMT201600212B/it unknown
- 2016-07-05 SM SM201600213T patent/SMT201600213B/it unknown
- 2016-07-13 HR HRP20160865TT patent/HRP20160865T1/hr unknown
- 2016-07-13 SM SM201600229T patent/SMT201600229B/it unknown
- 2016-07-13 CY CY20161100670T patent/CY1118126T1/el unknown
- 2016-08-21 IL IL247386A patent/IL247386A/en active IP Right Grant
- 2016-10-19 JP JP2016204854A patent/JP2017006152A/ja not_active Withdrawn
- 2016-10-25 JP JP2016208582A patent/JP6341972B2/ja active Active
-
2017
- 2017-01-04 US US15/398,410 patent/US9850462B2/en active Active
- 2017-05-24 US US15/604,021 patent/US9844212B2/en active Active
- 2017-10-22 IL IL255179A patent/IL255179B/en active IP Right Grant
- 2017-10-24 CY CY20171101102T patent/CY1119478T1/el unknown
- 2017-10-31 HR HRP20171666TT patent/HRP20171666T1/hr unknown
- 2017-11-13 US US15/810,900 patent/US10266803B2/en active Active
- 2017-11-20 JP JP2017222512A patent/JP6545773B2/ja active Active
-
2018
- 2018-06-12 IL IL259965A patent/IL259965B/en active IP Right Grant
- 2018-10-04 JP JP2018188847A patent/JP2018201528A/ja active Pending
- 2018-10-04 JP JP2018188846A patent/JP2018201527A/ja active Pending
- 2018-12-06 JP JP2018228851A patent/JP6963542B2/ja active Active
-
2019
- 2019-02-04 IL IL264634A patent/IL264634B/en active IP Right Grant
- 2019-02-06 US US16/269,477 patent/US20190153384A1/en not_active Abandoned
- 2019-03-11 US US16/298,308 patent/US20190203171A1/en not_active Abandoned
- 2019-04-30 HR HRP20190807TT patent/HRP20190807T1/hr unknown
- 2019-04-30 CY CY20191100459T patent/CY1122877T1/el unknown
- 2019-09-02 IL IL269078A patent/IL269078B/en active IP Right Grant
-
2020
- 2020-01-31 JP JP2020015538A patent/JP2020062061A/ja not_active Withdrawn
- 2020-02-12 US US16/788,532 patent/US20200239837A1/en not_active Abandoned
- 2020-06-05 JP JP2020098480A patent/JP7236409B2/ja active Active
-
2021
- 2021-01-25 JP JP2021009451A patent/JP2021061863A/ja not_active Withdrawn
- 2021-05-03 IL IL282872A patent/IL282872B/en unknown
-
2022
- 2022-03-07 JP JP2022034415A patent/JP2022066449A/ja not_active Withdrawn
- 2022-03-13 IL IL291301A patent/IL291301B2/en unknown
-
2023
- 2023-08-03 JP JP2023127047A patent/JP2023133554A/ja active Pending
- 2023-12-18 US US18/543,857 patent/US20240327785A1/en active Pending
-
2024
- 2024-12-09 JP JP2024214653A patent/JP2025027148A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060015957A1 (en) * | 1991-08-28 | 2006-01-19 | Genpharm International, Inc. | Transgenic non-human animals for producing chimeric antibodies |
| WO2000026373A1 (en) * | 1998-11-03 | 2000-05-11 | Babraham Institute | MURINE EXPRESSION OF HUMAN Igμ LOCUS |
| US20050060763A1 (en) * | 2001-06-21 | 2005-03-17 | Marianne Bruggeman | Mouse lambda light chain locus |
| US20030217373A1 (en) * | 2001-11-30 | 2003-11-20 | Green Larry L. | Transgenic animals bearing human Ig-lambda light chain genes |
| WO2009143472A2 (en) * | 2008-05-23 | 2009-11-26 | Aliva Biopharmaceuticals, Inc. | Method of generating single vl domain antibodies in transgenic animals |
| WO2010039900A2 (en) * | 2008-09-30 | 2010-04-08 | Aliva Biopharmaceuticals, Inc. | Non-human mammals for the production of chimeric antibodies |
Non-Patent Citations (1)
| Title |
|---|
| POPOV, A. V. et al., Journal of Experimental Medicine, 1999, vol. 189, pages 1611-1619 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240327785A1 (en) | Human lambda light chain mice | |
| AU2011271043B8 (en) | Mice expressing a light chain with human lambda variable and mouse constant regions | |
| AU2015275242B2 (en) | Hybrid light chain mice | |
| HK40010621A (en) | Mice expressing an immunoglobulin hybrid light chain | |
| AU2015275243A1 (en) | Mice expressing a light chain with human lambda variable and mouse constant regions | |
| HK1242732A1 (en) | Mice with humanised lambda variable gene segments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |